<DOC>
	<DOCNO>NCT01042067</DOCNO>
	<brief_summary>The study national multicenter prospective observational study , include 200 patient . The main purpose study explore detail influence genetic variability ( CYP enzymes vitamin K dependent protein ) dietary vitamin K status warfarin dosing , clinical effect adverse event emphasis initial phase treatment . The hypothesis genetic variability concern CYP enzyme vitamin K dependent protein predict dose adverse event warfarin treatment . The main aim individualize warfarin therapy establish treatment algorithm base genotype dietary vitamin K status make anticoagulation therapy warfarin secure .</brief_summary>
	<brief_title>Safer Warfarin Treatment</brief_title>
	<detailed_description />
	<mesh_term>Atrial Fibrillation</mesh_term>
	<mesh_term>Thrombosis</mesh_term>
	<mesh_term>Embolism</mesh_term>
	<mesh_term>Pulmonary Embolism</mesh_term>
	<mesh_term>Venous Thrombosis</mesh_term>
	<mesh_term>Vitamins</mesh_term>
	<mesh_term>Vitamin K</mesh_term>
	<mesh_term>Warfarin</mesh_term>
	<criteria>Caucasian &gt; 18 year age include study onset warfarin treatment target INR ( 23 atrial fibrillation , vein thrombosis , pulmonary embolism 2.53.5 prosthetic heart valve ) standard indication warfarin treatment Noncaucasian Clinical significant liver affection Heart failure , NYHA class IIIIV Noncompliant able accomplish protocol demand Not able give inform consent Longterm antibiotic therapy Malabsorption condition inflammatory bowel disease</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2011</verification_date>
	<keyword>warfarin</keyword>
	<keyword>genotyping</keyword>
	<keyword>vitamin K</keyword>
	<keyword>dose</keyword>
	<keyword>adverse event</keyword>
	<keyword>initial phase treatment</keyword>
	<keyword>algorithm</keyword>
</DOC>